Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

Exploiting synthetic lethal interactions for targeted cancer therapy

(2011) H. Christian Reinhardt et al.   CELL CYCLE

Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents

(2011) Jean-Damien Charrier et al.   JOURNAL OF MEDICINAL CHEMISTRY

Disulfiram Treatment Facilitates Phosphoinositide 3-Kinase Inhibition in Human Breast Cancer Cells In vitro and In vivo

(2010) H. Zhang et al.   CANCER RESEARCH

Targeted Radiosensitization of Cells Expressing Truncated DNA Polymerase  

(2010) S. Neijenhuis et al.   CANCER RESEARCH

Radiosensitization of Epidermal Growth Factor Receptor/HER2-Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status

(2010) R. J. Kimple et al.   CLINICAL CANCER RESEARCH

New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

(2010) Y. Dai et al.   CLINICAL CANCER RESEARCH

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

(2010) A. Mukhopadhyay et al.   CLINICAL CANCER RESEARCH

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

(2010) Cynthia X. Ma et al.   TRENDS IN MOLECULAR MEDICINE

The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2

(2009) Luke R.E. Harrison et al.   BIOCHEMICAL PHARMACOLOGY

PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts

(2009) C. Zhang et al.   CLINICAL CANCER RESEARCH

Bifunctional DNA Alkylator 1,3-Bis(2-chloroethyl)-1-nitrosourea Activates the ATR-Chk1 Pathway Independently of the Mismatch Repair Pathway

(2009) B. Cui et al.   MOLECULAR PHARMACOLOGY

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE

Keeping checkpoint kinases in line: new selective inhibitors in clinical trials

(2008) Susan Ashwell et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

(2008) A. Blasina et al.   MOLECULAR CANCER THERAPEUTICS

An Oncogene-Induced DNA Damage Model for Cancer Development

(2008) T. D. Halazonetis et al.   SCIENCE